Applications of miRNA, DNA methylation, and histone modifications on diagnosis and therapeutics of diabetic embryopathy

Daoyin Dong, E. Albert Reece, Peixin Yang*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In previous chapter of this book, we have elucidated that three epigenetic modalities - microRNA (miRNA), DNA methylation, and histone modifications - are possible pathological pathways causing diabetic embryopathy. This chapter discusses the potential of utilizing epigenetic biomarkers for early diagnosis of embryonic malformation in pregnancy, and the therapeutics for diabetic embryopathy based on modifying epigenetic changes. We show evidence that circulating miRNAs, intermediates of the DNA methylation cycle, and epigenetic profiles of circulating nucleosomes, such as DNA methylation and histone modifications, have become promising biomarker candidates for diagnosis and prognosis of diabetic embryopathy. We also describe studies which have targeted the activity of hyperglycemia-induced miRNAs, using mimics or inhibitors; DNA methylation, using nutritional supplements; and histone modifying enzymes, using chemical inhibitors, to prevent diabetic embryopathy. Although we have the promising progress, the development of effective biomarkers and therapeutics for diabetic embryopathy still face many challenges.

Original languageEnglish (US)
Title of host publicationHandbook of Nutrition, Diet, and Epigenetics
PublisherSpringer International Publishing
Pages1347-1359
Number of pages13
Volume2
ISBN (Electronic)9783319555300
ISBN (Print)9783319555294
DOIs
StatePublished - Jan 5 2019
Externally publishedYes

Keywords

  • Biomarker
  • DNA methylation
  • Embryopathy
  • Histone modifications
  • Maternal diabetes
  • miRNA
  • Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Applications of miRNA, DNA methylation, and histone modifications on diagnosis and therapeutics of diabetic embryopathy'. Together they form a unique fingerprint.

Cite this